Heart Failure New Drug Acquisition and Revenue Surge: Nasdaq Bio Expands Cardiovascular Portfolio

Esperion Therapeutics, Inc. (NASDAQ: ESPR), a biotech specialist in cardiovascular metabolic diseases, has entered into a merger agreement under Delaware law to combine its subsidiary, Cirrus Transaction Subsidiary, with Corstasis Therapeutics, making Corstasis a wholly owned subsidiary. In addition to a $75 million upfront cash payment, the deal includes contingent consideration tied to regulatory and commercialization milestones as well as revenue-based profit sharing.

On March 10, the company reported its fourth-quarter and full-year 2025 results, driven by its bempedoic acid–based cardiovascular products and a $90 million milestone payment from partner Otsuka. Annual revenue rose 21% year-over-year to $403.1 million, while fourth-quarter revenue reached $168.4 million.

Following the earnings release, major financial media noted that Esperion returned to profitability in Q4 2025, although it still recorded a modest net loss for the full year. Analysts highlighted investor interest in the company’s revenue growth, improved earnings trajectory, and the strategic impact of adding the heart-failure nasal spray Enbumyst through the Corstasis acquisition.

Esperion currently markets Nexletol and Nexlizet—oral bempedoic acid therapies designed to lower LDL cholesterol for hyperlipidemia treatment and cardiovascular risk reduction—and is expanding its pipeline with candidates such as ESP-2001, an ACLY inhibitor for cholestatic liver disorders.

The heart-failure and cardio-metabolic treatment market is benefiting from aging populations and rising chronic-disease prevalence, driving steady prescription demand. Competition is intensifying in non-oral formulations, exemplified by loop-diuretic nasal sprays like Corstasis’s Enbumyst.